These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 101456)

  • 1. Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally.
    Levine MM; Hughes TP; Young CR; O'Donnell S; Craig JP; Holley HP; Bergquist EJ
    Infect Immun; 1978 Jul; 21(1):158-62. PubMed ID: 101456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine.
    Peterson JW
    Infect Immun; 1979 Nov; 26(2):528-33. PubMed ID: 546785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenicity of cholera toxoid in humans.
    Germanier R; Fürer E; Varallyay S; Inderbitzin TM
    J Infect Dis; 1977 Apr; 135(4):512-6. PubMed ID: 856918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against experimental cholera by oral or parenteral immunization.
    Peterson JW
    Infect Immun; 1979 Nov; 26(2):594-8. PubMed ID: 546789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera.
    Pierce NF; Cray WC; Sircar BK
    Infect Immun; 1978 Jul; 21(1):185-93. PubMed ID: 711314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cholera toxoid in an enzyme-linked immunosorbent assay for antitoxin.
    Cruce DD; Wachsmuth IK; Feeley JC
    Diagn Immunol; 1983; 1(2):87-9. PubMed ID: 6680095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholera toxoid boosts serum Escherichia coli antitoxin in humans.
    Nalin DR; al-Mahmud A; Curlin G; Ahmed A; Peterson J
    Infect Immun; 1974 Oct; 10(4):747-9. PubMed ID: 4609909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen.
    Rappaport RS; Pierzchala WA; Bonde G; McCann T; Rubin BA
    Infect Immun; 1976 Sep; 14(3):687-93. PubMed ID: 823117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal immunization with soluble bacterial antigens: the example of cholera toxoid.
    Pierce NF
    Ciba Found Symp; 1976; (42):129-47. PubMed ID: 1086763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a purified cholera toxoid. II. Preparation of a stable, antigenic toxoid by reaction of purified toxin with glutaraldehyde.
    Rappaport RS; Bonde G; McCann T; Rubin BA; Tint H
    Infect Immun; 1974 Feb; 9(2):304-17. PubMed ID: 4205946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A toxoid prepared from cholera toxin by iodination.
    Heneine IF; Lahmann WM; Rocha OA
    Braz J Med Biol Res; 1992; 25(9):913-7. PubMed ID: 1342838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response of the intestinal mucosa to cholera toxoid.
    Pierce NF; Sack RB
    J Infect Dis; 1977 Aug; 136 Suppl():S113-7. PubMed ID: 894085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity in experimental cholera: effect of parenteral immunization with vaccines and toxoid.
    Sinha VB; Bhaskaran K
    Bull World Health Organ; 1973; 49(6):605-13. PubMed ID: 4548387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adjuvant effect of pertussis endotoxin protein in modulating the immune response to cholera toxoid in mice.
    Sultzer BM; Craig JP; Castagna R
    Dev Biol Stand; 1985; 61():225-32. PubMed ID: 2872108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation.
    Karlsen TH; Sommerfelt H; Klomstad S; Andersen PK; Strand TA; Ulvik RJ; Ahrén C; Grewal HM
    Infect Immun; 2003 Jul; 71(7):3909-13. PubMed ID: 12819076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.
    Jertborn M; Svennerholm AM; Holmgren J
    J Clin Microbiol; 1986 Aug; 24(2):203-9. PubMed ID: 3528211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral administration of toxoid to dogs.
    Pierce NF; Sack RB; Sircar BK
    J Infect Dis; 1977 Jun; 135(6):888-96. PubMed ID: 864285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunological consequences of feeding cholera toxin. I. Feeding cholera toxin suppresses the induction of systemic delayed-type hypersensitivity but not humoral immunity.
    Kay RA; Ferguson A
    Immunology; 1989 Mar; 66(3):410-5. PubMed ID: 2703255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.
    Clements ML; Levine MM; Young CR; Black RE; Lim YL; Robins-Browne RM; Craig JP
    J Infect Dis; 1982 Apr; 145(4):465-73. PubMed ID: 7069227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.